Medtronic Launches yet Another Back Pain Neurostim Study
Medical device company Medtronic continues to battle for its position in the market for neurostimulation systems that treat pain with a new clinical study of treatments for chronic back pain.
Medtech titan Medtronic  (NYSE:MDT ) enrolled the initial patients in its SubQStim II pivotal clinical trial, evaluating the use of peripheral nerve stimulation in treatment of chronic back pain.
The new study is the latest in a handful of neurostimulation trials launched by the medical device giant as it continues to battle rivals in the market for neurostimulation systems that treat chronic pain.
Patients enrolled in the SubQStim II trial received implanted electrical leads under the skin of the lower back. The leads connect to an electrical pulse generator that delivers mild pulses of energy to interrupt pain signal on their way to the brain.